Zydus Lifesciences Limited CC-Mar25.pdf · 2025-05-20
Hello, yes. Congratulations and good afternoon. Firstly, o n Revlimid, after the patent expiry, given the nature of the product , the distribution, can we see Revlimid still being a significant $50 million odd kind of sustainable opportunity for FY27 and beyond that?
Okay. In terms of the composition of our US base for FY27, could you give an idea of what percentage of contribution can come from NDAs or 505(b)(2) opportunities in FY27, or what’s the long - term goal there? What percentage of US revenue that can scale up to?